Sanofi Stock Price, News & Analysis (NYSE:SNY)

$44.60 -0.31 (-0.69 %)
(As of 01/18/2018 02:13 PM ET)
Previous Close$44.91
Today's Range$44.52 - $44.81
52-Week Range$39.42 - $50.65
Volume912,900 shs
Average Volume1.38 million shs
Market Capitalization$112.10 billion
P/E Ratio20.27
Dividend Yield2.45%
Beta0.86

About Sanofi (NYSE:SNY)

Sanofi logoSanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company's segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company's pharmaceuticals operations. The Vaccines segment is dedicated to vaccines and includes the commercial operations of the Company's vaccines division Sanofi Pasteur and dedicated research and development, production and marketing activities for the Company's vaccines operations. Its Rare Diseases products include Cerezyme, Cerdelga, Myozyme and Lumizyme, Fabrazyme, and Aldurazyme.

Receive SNY News and Ratings via Email

Sign-up to receive the latest news and ratings for SNY and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceuticals
Sub-IndustryN/A
SectorHealthcare
SymbolNYSE:SNY
CUSIPN/A
Phone+33-1-53774000

Debt

Debt-to-Equity Ratio0.26%
Current Ratio1.59%
Quick Ratio1.16%

Price-To-Earnings

Trailing P/E Ratio20.2727272727273
Forward P/E Ratio13.35
P/E Growth2.56

Sales & Book Value

Annual Sales$37.43 billion
Price / Sales3.00
Cash Flow$4.58 per share
Price / Cash9.73
Book Value$25.11 per share
Price / Book1.78

Profitability

Trailing EPS$2.20
Net Income$4.86 billion
Net Margins25.44%
Return on Equity25.19%
Return on Assets14.09%

Miscellaneous

Employees106,859
Outstanding Shares2,521,510,000

Sanofi (NYSE:SNY) Frequently Asked Questions

What is Sanofi's stock symbol?

Sanofi trades on the New York Stock Exchange (NYSE) under the ticker symbol "SNY."

How often does Sanofi pay dividends? What is the dividend yield for Sanofi?

Sanofi announced an annual dividend on Friday, February 17th. Investors of record on Monday, May 15th will be given a dividend of $1.5771 per share on Wednesday, June 7th. This represents a dividend yield of 3.65%. The ex-dividend date of this dividend is Thursday, May 11th. This is an increase from Sanofi's previous annual dividend of $1.10. View Sanofi's Dividend History.

How were Sanofi's earnings last quarter?

Sanofi SA (NYSE:SNY) announced its quarterly earnings results on Thursday, November, 2nd. The company reported $1.00 EPS for the quarter, hitting analysts' consensus estimates of $1.00. Sanofi had a net margin of 25.44% and a return on equity of 25.19%. View Sanofi's Earnings History.

When will Sanofi make its next earnings announcement?

Sanofi is scheduled to release their next quarterly earnings announcement on Wednesday, February, 7th 2018. View Earnings Estimates for Sanofi.

Where is Sanofi's stock going? Where will Sanofi's stock price be in 2018?

10 equities research analysts have issued 1-year target prices for Sanofi's stock. Their predictions range from $48.00 to $55.00. On average, they anticipate Sanofi's share price to reach $51.50 in the next year. View Analyst Ratings for Sanofi.

What are Wall Street analysts saying about Sanofi stock?

Here are some recent quotes from research analysts about Sanofi stock:

  • 1. According to Zacks Investment Research, "Sanofi’s Diabetes franchise is under significant pressure with key product, Lantus facing increasing competitive pressure at the payor level and the presence of biosimilar competition in several European markets and Japan. Sanofi’s outlook for its Diabetes franchise is also bleak due to a tough U.S. payer environment. At the Q2 conference call, management warned that US diabetes sales will decline faster in the second half. Other headwinds include generic competition and slower-than-expected uptake of new products like Praluent. Sanofi’s shares have underperformed the industry in the past three months. However, Sanofi's focus on streamlining its business and pursuing business development deals is encouraging. Further, new drugs like Aubagio and Lemtrada are likely to continue doing well. Estimates have remained stable ahead of Q3 earnings release. Sanofi has a positive record of earnings surprises in recent quarters." (10/6/2017)
  • 2. Argus analysts commented, "The company also has a strong new drug pipeline that includes Toujeo, a next-generation insulin product, and dipilumab, for atopic dermatitis and other inflammatory conditions," the analyst said.See also: Where Does Zika Virus Vaccine Research Stand Now? FY18 ExpectationsArgus expects the company's 2017 revenues from continuing operations to benefit from the recent acquisition of Boehringer Ingelheim's consumer health business and higher sales of multiple sclerosis products. At the same time, the firm expects reduced diabetes drug sales.The firm also sees margin pressure due to pricing pressures for diabetes products in the U.S. and costs related to the launch of Dupixent and Kevzara, partly offset by a sales force reorganization and other cost-savings initiatives."In 2018, we expect continued solid demand for multiple sclerosis drugs and increased sales in emerging markets to outweigh weaker sales of diabetes drugs, and look for the company's cost-savings program to benefit margins," (9/1/2017)

Who are some of Sanofi's key competitors?

Who are Sanofi's key executives?

Sanofi's management team includes the folowing people:

  • Serge Weinberg, Independent Chairman of the Board (Age 66)
  • Olivier Brandicourt, Chairman of the Executive Committee, Chief Executive Officer, Director (Age 61)
  • Jerome Contamine, Executive Vice President, Chief Financial Officer, Member of the Executive Committee (Age 59)
  • Karen Marie Linehan, Executive Vice President, Legal Affairs and General Counsel; Member of the Executive Committee (Age 58)
  • Olivier Charmeil, Executive Vice President and General Manager, General Medicines & Emerging Markets; Member of the Executive Committee (Age 54)
  • Roberto Pucci, Executive Vice President, Human Resources; Member of the Executive Committee (Age 53)
  • Peter Guenter, Executive Vice President, Diabetes & Cardiovascular; Member of the Executive Committee (Age 55)
  • David Loew, Executive Vice President, Sanofi Pasteur; Member of the Executive Committee
  • Philippe Luscan, Executive Vice President, Global Industrial Affairs; Member of the Executive Committee (Age 55)
  • Alan J. Main Ph.D., Executive Vice President, Consumer Healthcare; Member of the Executive Committee (Age 63)

Who owns Sanofi stock?

Sanofi's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Foundation Resource Management Inc. (0.01%), Bank of Montreal Can (0.01%), Beacon Financial Group (0.00%), Cullinan Associates Inc. (0.00%), Clean Yield Group (0.00%) and Fulton Bank N.A. (0.00%). View Institutional Ownership Trends for Sanofi.

Who sold Sanofi stock? Who is selling Sanofi stock?

Sanofi's stock was sold by a variety of institutional investors in the last quarter, including Bank of Montreal Can, Fulton Bank N.A., First Bank & Trust, Benjamin F. Edwards & Company Inc., Foundation Resource Management Inc., Atria Investments LLC and Bremer Trust National Association. View Insider Buying and Selling for Sanofi.

Who bought Sanofi stock? Who is buying Sanofi stock?

Sanofi's stock was acquired by a variety of institutional investors in the last quarter, including Clean Yield Group, Cullinan Associates Inc., Beacon Financial Group, BLB&B Advisors LLC and E&G Advisors LP. View Insider Buying and Selling for Sanofi.

How do I buy Sanofi stock?

Shares of Sanofi can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Sanofi's stock price today?

One share of Sanofi stock can currently be purchased for approximately $44.60.

How big of a company is Sanofi?

Sanofi has a market capitalization of $112.10 billion and generates $37.43 billion in revenue each year. The company earns $4.86 billion in net income (profit) each year or $2.20 on an earnings per share basis. Sanofi employs 106,859 workers across the globe.

How can I contact Sanofi?

Sanofi's mailing address is 54 rue la Boetie, PARIS, 75008, France. The company can be reached via phone at +33-1-53774000 or via email at [email protected]


MarketBeat Community Rating for Sanofi (SNY)

Community Ranking:  2.1 out of 5 (star star)
Outperform Votes:  256 (Vote Outperform)
Underperform Votes:  342 (Vote Underperform)
Total Votes:  598
MarketBeat's community ratings are surveys of what our community members think about Sanofi and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Sanofi (NYSE:SNY) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 2.102.182.302.25
Ratings Breakdown: 1 Sell Rating(s)
7 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
7 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
5 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
7 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $51.50$51.50$53.50$74.00
Price Target Upside: 17.80% upside19.30% upside9.71% upside53.53% upside

Sanofi (NYSE:SNY) Consensus Price Target History

Price Target History for Sanofi (NYSE:SNY)

Sanofi (NYSE:SNY) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/11/2018JPMorgan Chase & Co.Reiterated RatingNeutralLowView Rating Details
1/2/2018Nord/LBReiterated RatingNeutralLowView Rating Details
12/18/2017CowenSet Price TargetHold$48.00LowView Rating Details
12/6/2017Bank of AmericaDowngradeBuy -> NeutralLowView Rating Details
12/1/2017Morgan StanleyDowngradeOverweight -> UnderweightLowView Rating Details
11/15/2017BarclaysUpgradeUnderweight -> Equal WeightN/AView Rating Details
9/1/2017ArgusReiterated RatingBuy$55.00MediumView Rating Details
5/11/2017Berenberg BankDowngradeBuy -> HoldLowView Rating Details
3/9/2017Liberum CapitalInitiated CoverageHold -> HoldLowView Rating Details
2/9/2017NatixisUpgradeNeutral -> BuyN/AView Rating Details
1/10/2017Leerink SwannReiterated RatingOutperformN/AView Rating Details
1/8/2017Goldman Sachs GroupReiterated RatingHoldN/AView Rating Details
9/23/2016Piper Jaffray CompaniesInitiated CoverageNeutralN/AView Rating Details
9/14/2016Jefferies GroupReiterated RatingHoldN/AView Rating Details
9/13/2016BNP ParibasUpgradeUnderperform -> NeutralN/AView Rating Details
6/28/2016CitigroupReiterated RatingNeutralN/AView Rating Details
4/12/2016Chardan CapitalReiterated RatingBuyN/AView Rating Details
2/10/2016Sanford C. BernsteinLower Price TargetMarket-Perform$52.00 -> $45.00N/AView Rating Details
(Data available from 1/18/2016 forward)

Earnings

Sanofi (NYSE:SNY) Earnings History and Estimates Chart

Earnings by Quarter for Sanofi (NYSE:SNY)

Sanofi (NYSE SNY) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/7/2018$0.68N/AView Earnings Details
11/2/2017Q3 2017$1.00$1.00ViewN/AView Earnings Details
7/31/20176/30/2017$0.74$0.74$8.71 billion$8.66 billionViewN/AView Earnings Details
4/28/20173/31/2017$0.73$0.76$8.40 billion$8.65 billionViewN/AView Earnings Details
2/8/2017Q416$0.66$0.67$9.87 billion$8.88 billionViewN/AView Earnings Details
10/28/2016Q3 2016$0.86$1.00ViewN/AView Earnings Details
7/29/2016Q2 2016$0.74$0.74ViewN/AView Earnings Details
4/29/2016Q1 2016$0.72$0.74ViewN/AView Earnings Details
2/9/2016Q4 2015$0.69$0.72ViewN/AView Earnings Details
10/29/2015Q315$0.88$0.89$10.97 billion$10.67 billionViewN/AView Earnings Details
7/30/2015Q2 2015$0.72$0.78ViewN/AView Earnings Details
4/30/2015Q115$0.61$0.73$9.21 billion$9.78 billionViewN/AView Earnings Details
2/5/2015Q4$0.89$0.79$11.34 billion$10.39 billionViewN/AView Earnings Details
10/28/2014Q3 2014$0.94$0.94ViewN/AView Earnings Details
7/31/2014Q2$0.79$0.72$11.19 billion$10.82 billionViewN/AView Earnings Details
4/29/2014Q114$0.84$0.81$11.19 billion$10.88 billionViewN/AView Earnings Details
2/6/2014Q4$0.88$0.93ViewN/AView Earnings Details
10/30/2013$1.01$0.93ViewN/AView Earnings Details
8/1/2013Q2 2013$0.89$0.73ViewN/AView Earnings Details
5/2/2013Q1 2013$0.89$0.80ViewN/AView Earnings Details
2/7/2013Q4 2012$0.77$0.78ViewN/AView Earnings Details
10/25/2012Q3 2012$0.99$1.10ViewN/AView Earnings Details
7/26/2012Q2 2012$0.84$0.90ViewN/AView Earnings Details
4/27/2012Q1 2012$1.13$1.22ViewN/AView Earnings Details
2/8/2012Q4 2011$1.00$1.02ViewN/AView Earnings Details
11/3/2011Q3 2011$1.21$1.24ViewN/AView Earnings Details
7/28/2011Q2 2011$1.18$0.56ViewN/AView Earnings Details
4/28/2011Q1 2011$1.16$1.22ViewN/AView Earnings Details
2/9/2011Q4 2010$0.95$0.96ViewN/AView Earnings Details
10/28/2010Q3 2010$1.17$1.30ViewN/AView Earnings Details
7/29/2010Q2 2010$1.08$0.85ViewN/AView Earnings Details
4/29/2010Q1 2010$1.18$1.23ViewN/AView Earnings Details
2/10/2010Q4 2009$0.92$0.94ViewN/AView Earnings Details
10/30/2009Q3 2009$1.21$1.26ViewN/AView Earnings Details
7/29/2009Q2 2009$1.04$1.24ViewN/AView Earnings Details
4/29/2009Q1 2009$0.86$1.08ViewN/AView Earnings Details
2/11/2009Q4 2008$0.82$0.82ViewN/AView Earnings Details
10/31/2008Q3 2008$0.97$1.07ViewN/AView Earnings Details
7/31/2008Q2 2008$1.07$1.04ViewN/AView Earnings Details
4/30/2008Q1 2008$2.48$2.14ViewN/AView Earnings Details
2/12/2008Q4 2007$0.76$0.82ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Sanofi (NYSE:SNY) Earnings Estimates

Current Year EPS Consensus Estimate: $3.34 EPS
Next Year EPS Consensus Estimate: $3.42 EPS

Dividends

Sanofi (NYSE:SNY) Dividend Information

Most Recent Dividend:6/7/2017
Annual Dividend:$1.10
Dividend Yield:2.47%
Dividend Growth:-4.90% (3 Year Average)
Payout Ratio:50.00% (Trailing 12 Months of Earnings)
32.93% (Based on This Year's Estimates)
32.16% (Based on Next Year's Estimates)
Dividend Payments by Quarter for Sanofi (NYSE:SNY)

Sanofi (NYSE:SNY) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
2/17/2017annual$1.583.65%5/11/20175/15/20176/7/2017
2/22/2016Annual$1.105/5/20165/9/20166/1/2016
2/26/2015special$1.623.91%5/6/20155/8/20156/2/2015
(Data available from 1/1/2013 forward)

Insider Trades

Sanofi (NYSE SNY) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 1.00%
Institutional Ownership Percentage: 9.08%
Insider Trades by Quarter for Sanofi (NYSE:SNY)
Institutional Ownership by Quarter for Sanofi (NYSE:SNY)

Sanofi (NYSE SNY) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/24/2017SanofiMajor ShareholderBuy105,820$482.04$51,009,472.80View SEC Filing  
8/23/2017SanofiMajor ShareholderBuy60,595$478.98$29,023,793.10View SEC Filing  
7/9/2014SanofiMajor ShareholderBuy195,000$308.27$60,112,650.00View SEC Filing  
7/8/2014SanofiMajor ShareholderBuy153,000$311.67$47,685,510.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Sanofi (NYSE SNY) News Headlines

Source:
DateHeadline
Jefferies Group Research Analysts Lift Earnings Estimates for Sanofi SA (SNY)Jefferies Group Research Analysts Lift Earnings Estimates for Sanofi SA (SNY)
www.americanbankingnews.com - January 17 at 7:28 AM
Sanofi (SNY) Stock Rating Reaffirmed by UBS GroupSanofi (SNY) Stock Rating Reaffirmed by UBS Group
www.americanbankingnews.com - January 15 at 11:02 AM
Sanofi SA (SNY) Given Consensus Rating of "Hold" by BrokeragesSanofi SA (SNY) Given Consensus Rating of "Hold" by Brokerages
www.americanbankingnews.com - January 13 at 2:28 AM
Sanofi (SNY) Receives Neutral Rating from JPMorgan Chase & Co.Sanofi (SNY) Receives Neutral Rating from JPMorgan Chase & Co.
www.americanbankingnews.com - January 11 at 6:06 AM
Safety Fears Threaten Global Dengue Vaccine Effort - WSJ - Wall Street JournalSafety Fears Threaten Global Dengue Vaccine Effort - WSJ - Wall Street Journal
www.wsj.com - January 9 at 6:34 AM
XenoPort (XNPT) versus Sanofi (SNY) Critical AnalysisXenoPort (XNPT) versus Sanofi (SNY) Critical Analysis
www.americanbankingnews.com - January 2 at 9:32 AM
Inside Sanofi Pasteur’s 3Q17 PerformanceInside Sanofi Pasteur’s 3Q17 Performance
finance.yahoo.com - December 28 at 5:07 PM
Behind Sanofi’s Diabetes and Cardiovascular Portfolio in 3Q17Behind Sanofi’s Diabetes and Cardiovascular Portfolio in 3Q17
finance.yahoo.com - December 28 at 5:07 PM
Reading Sanofi’s End-of-Year Analyst EstimatesReading Sanofi’s End-of-Year Analyst Estimates
finance.yahoo.com - December 28 at 5:07 PM
Behind Sanofi’s Established Prescription Products in 3Q17Behind Sanofi’s Established Prescription Products in 3Q17
finance.yahoo.com - December 27 at 9:55 AM
Behind Sanofi’s Genzyme Business in 3Q17Behind Sanofi’s Genzyme Business in 3Q17
finance.yahoo.com - December 27 at 9:55 AM
Sanofi (SNY) Stock Rating Reaffirmed by Nord/LBSanofi (SNY) Stock Rating Reaffirmed by Nord/LB
www.americanbankingnews.com - December 27 at 8:48 AM
Inside Sanofi’s Quarterly Revenue Trend in 3Q17Inside Sanofi’s Quarterly Revenue Trend in 3Q17
finance.yahoo.com - December 26 at 1:24 PM
$10.38 Billion in Sales Expected for Sanofi SA (SNY) This Quarter$10.38 Billion in Sales Expected for Sanofi SA (SNY) This Quarter
www.americanbankingnews.com - December 21 at 7:12 AM
 Analysts Anticipate Sanofi SA (SNY) Will Announce Earnings of $0.68 Per Share Analysts Anticipate Sanofi SA (SNY) Will Announce Earnings of $0.68 Per Share
www.americanbankingnews.com - December 19 at 9:32 AM
Sanofi SA (SNY) Receives Consensus Rating of "Hold" from BrokeragesSanofi SA (SNY) Receives Consensus Rating of "Hold" from Brokerages
www.americanbankingnews.com - December 19 at 2:14 AM
Sanofi (SNY) Given a $48.00 Price Target at CowenSanofi (SNY) Given a $48.00 Price Target at Cowen
www.americanbankingnews.com - December 18 at 6:14 PM
Sanofi (SNY) Rating Reiterated by J P Morgan Chase & CoSanofi (SNY) Rating Reiterated by J P Morgan Chase & Co
www.americanbankingnews.com - December 15 at 12:52 AM
Sanofi CEO says M&A targets in oncology are very expensiveSanofi CEO says M&A targets in oncology are 'very expensive'
finance.yahoo.com - December 14 at 3:18 PM
Sanofi Genzyme issues recall for contaminated arthritis gelSanofi Genzyme issues recall for contaminated arthritis gel
www.msn.com - December 12 at 3:17 PM
Buy Celgene And Regeneron On The Dips As Insiders Are Buying - Seeking AlphaBuy Celgene And Regeneron On The Dips As Insiders Are Buying - Seeking Alpha
seekingalpha.com - December 12 at 6:04 AM
Sanofi (SNY) Cut to Neutral at Bank of AmericaSanofi (SNY) Cut to Neutral at Bank of America
www.americanbankingnews.com - December 6 at 9:20 PM
Sanofi: Toujeo Meets Primary Study Objective In BRIGHT Study - Quick FactsSanofi: Toujeo Meets Primary Study Objective In BRIGHT Study - Quick Facts
www.nasdaq.com - December 5 at 3:18 PM
Philippines halts sale of Sanofi dengue vaccinePhilippines halts sale of Sanofi dengue vaccine
seekingalpha.com - December 5 at 5:35 AM
Philippines halts sale of Sanofi dengue vaccine amid health riskPhilippines halts sale of Sanofi dengue vaccine amid health risk
www.cnbc.com - December 4 at 10:37 PM
Sanofis Toujeo on par with Novos Tresiba in head-to-head study in type 2 diabetics - Seeking AlphaSanofi's Toujeo on par with Novo's Tresiba in head-to-head study in type 2 diabetics - Seeking Alpha
seekingalpha.com - December 4 at 3:17 PM
Sanofis Toujeo® met main objective in head-to-head study versus insulin degludecSanofi's Toujeo® met main objective in head-to-head study versus insulin degludec
feeds.benzinga.com - December 4 at 1:26 AM
$10.38 Billion in Sales Expected for Sanofi (SNY) This Quarter$10.38 Billion in Sales Expected for Sanofi (SNY) This Quarter
www.americanbankingnews.com - December 3 at 4:40 AM
Sanofi (SNY) Ends Development of Clostridium Difficile VaccineSanofi (SNY) Ends Development of Clostridium Difficile Vaccine
www.streetinsider.com - December 2 at 3:17 PM
Sanofi (SNY) Ends Development of Clostridium Difficile Vaccine - StreetInsider.comSanofi (SNY) Ends Development of Clostridium Difficile Vaccine - StreetInsider.com
www.streetinsider.com - December 2 at 7:37 AM
Teva Pharmaceutical Industries (TEVA) and Sanofi (SNY) Head-To-Head SurveyTeva Pharmaceutical Industries (TEVA) and Sanofi (SNY) Head-To-Head Survey
www.americanbankingnews.com - December 2 at 7:24 AM
Sanofi (SNY) Cut to "Underweight" at Morgan StanleySanofi (SNY) Cut to "Underweight" at Morgan Stanley
www.americanbankingnews.com - December 1 at 9:16 PM
Zacks: Brokerages Expect Sanofi (SNY) Will Post Earnings of $0.69 Per ShareZacks: Brokerages Expect Sanofi (SNY) Will Post Earnings of $0.69 Per Share
www.americanbankingnews.com - December 1 at 5:38 PM
Robust Quant Score Metrics Drive Ranking of Sanofi (SNY) to Buy - Investorplace.comRobust Quant Score Metrics Drive Ranking of Sanofi (SNY) to Buy - Investorplace.com
investorplace.com - December 1 at 3:18 PM
Morning Movers: Ulta Tanks on Earnings; Sanofi Slips on DowngradeMorning Movers: Ulta Tanks on Earnings; Sanofi Slips on Downgrade
finance.yahoo.com - December 1 at 3:18 PM
BioTelemetry: Onduo Collaboration Is A Huge Growth Opportunity - Seeking AlphaBioTelemetry: Onduo Collaboration Is A Huge Growth Opportunity - Seeking Alpha
seekingalpha.com - December 1 at 6:25 AM
Shire Appoints Andreas Busch, Ph D as Head of Research and Development and Chief Scientific OfficerShire Appoints Andreas Busch, Ph D as Head of Research and Development and Chief Scientific Officer
feeds.benzinga.com - December 1 at 3:53 AM
Sanofi (SNY) Provides Updates on Dengue Vaccine; New Analysis of Dengvaxia Data Found Differences in ... - StreetInsider.comSanofi (SNY) Provides Updates on Dengue Vaccine; New Analysis of Dengvaxia Data Found Differences in ... - StreetInsider.com
www.streetinsider.com - November 30 at 6:10 AM
Voluntis integriert Insulia® in die virtuelle Diabetesklinik von OnduoVoluntis integriert Insulia® in die virtuelle Diabetesklinik von Onduo
www.prnewswire.com - November 28 at 1:36 PM
Sanofi (SNY) Earnings Growth Hurt RatingSanofi (SNY) Earnings Growth Hurt Rating
investorplace.com - November 24 at 10:46 AM
Sanofi (SNY) Given Consensus Rating of "Hold" by AnalystsSanofi (SNY) Given Consensus Rating of "Hold" by Analysts
www.americanbankingnews.com - November 24 at 2:14 AM
Top 10 Largest Pharmaceutical Companies By Revenue in 2017Top 10 Largest Pharmaceutical Companies By Revenue in 2017
finance.yahoo.com - November 23 at 12:58 PM
Amicus Therapeutics (FOLD) & Sanofi (SNY) Head-To-Head ContrastAmicus Therapeutics (FOLD) & Sanofi (SNY) Head-To-Head Contrast
www.americanbankingnews.com - November 21 at 1:22 AM
SNY January 2018 Options Begin TradingSNY January 2018 Options Begin Trading
www.nasdaq.com - November 20 at 3:27 PM
Drooping Earnings Growth Downgrades Sanofi (SNY) to Hold - Investorplace.comDrooping Earnings Growth Downgrades Sanofi (SNY) to Hold - Investorplace.com
www.investorplace.com - November 18 at 12:29 AM
Drooping Earnings Growth Downgrades Sanofi (SNY) to HoldDrooping Earnings Growth Downgrades Sanofi (SNY) to Hold
investorplace.com - November 17 at 2:42 PM
Termeer protege scores $27M for Genzyme rare disease spinoffTermeer protege scores $27M for Genzyme rare disease spinoff
www.bizjournals.com - November 17 at 1:13 PM
How Did Sanofi Pasteur Perform in 3Q17?How Did Sanofi Pasteur Perform in 3Q17?
finance.yahoo.com - November 16 at 6:32 PM
Behind Sanofi’s Generics and Consumer Healthcare Business in 3Q17Behind Sanofi’s Generics and Consumer Healthcare Business in 3Q17
finance.yahoo.com - November 16 at 8:35 AM
Behind Sanofi’s Established Product Performance in 3Q17Behind Sanofi’s Established Product Performance in 3Q17
finance.yahoo.com - November 15 at 3:38 PM

SEC Filings

Sanofi (NYSE:SNY) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Sanofi (NYSE:SNY) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Sanofi (NYSE SNY) Stock Chart for Thursday, January, 18, 2018

Loading chart…

This page was last updated on 1/18/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.